Ikhlaq Ahmed , Mohammed Qutishat , Rima Ikhlaq , Nishant Goyal , Salim AL-Huseini
{"title":"Prefrontal cortex modulation using transcranial direct current stimulation in opioid craving: A sham-control double-blind study","authors":"Ikhlaq Ahmed , Mohammed Qutishat , Rima Ikhlaq , Nishant Goyal , Salim AL-Huseini","doi":"10.1016/j.genhosppsych.2025.06.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Opioid addiction, a major global health crisis, has necessitated innovative therapeutic approaches. This study aims to investigate the efficacy of Transcranial Direct Current Stimulation (tDCS) targeting the right dorsolateral prefrontal cortex (DLPFC) in reducing cravings among individuals with opioid dependence.</div></div><div><h3>Method</h3><div>In this single-centre, double-blind, randomized, sham-controlled trial, 40 male inpatients with opioid dependence at the Central Institute of Psychiatry (Ranchi, India) were allocated to either active right-DLPFC tDCS (2 mA, 20 min) or sham stimulation for five consecutive days. Craving and psychosocial functioning were assessed via the Obsessive–Compulsive Drug Use Scale (OCDUS) and Addiction Severity Index (ASI) at baseline, immediately post-treatment, and at 2- and 4-week follow-ups. Repeated-measures ANOVA tested group × time differences.</div></div><div><h3>Results</h3><div>At baseline, OCDUS scores did not differ between groups (Active: 32.00 ± 2.47 vs. Sham: 31.60 ± 2.85; F (1,38) = 0.582, <em>p</em> = 0.582, η<sup>2</sup>p = 0.015). Following treatment, the Active group showed markedly greater reductions in craving than Sham at Day 5 (10.35 ± 2.21 vs. 24.25 ± 5.29; F(1,38) = 956.5, <em>p</em> < 0.001, η<sup>2</sup>ₚ = 0.672) and Day 14 (6.30 ± 1.98 vs. 20.75 ± 5.22; F(1,38) = 99.56, p < 0.001, η<sup>2</sup>ₚ = 0.503), with effects maintained at Day 28 (5.75 ± 1.65 vs. 23.35 ± 6.07).</div></div><div><h3>Conclusion</h3><div>Five sessions of right-DLPFC tDCS produced rapid, significant, and sustained reductions in opioid craving compared with sham, supporting its promise as an adjunctive treatment in opioid use disorder.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"96 ","pages":"Pages 78-84"},"PeriodicalIF":3.7000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"General hospital psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163834325001331","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Opioid addiction, a major global health crisis, has necessitated innovative therapeutic approaches. This study aims to investigate the efficacy of Transcranial Direct Current Stimulation (tDCS) targeting the right dorsolateral prefrontal cortex (DLPFC) in reducing cravings among individuals with opioid dependence.
Method
In this single-centre, double-blind, randomized, sham-controlled trial, 40 male inpatients with opioid dependence at the Central Institute of Psychiatry (Ranchi, India) were allocated to either active right-DLPFC tDCS (2 mA, 20 min) or sham stimulation for five consecutive days. Craving and psychosocial functioning were assessed via the Obsessive–Compulsive Drug Use Scale (OCDUS) and Addiction Severity Index (ASI) at baseline, immediately post-treatment, and at 2- and 4-week follow-ups. Repeated-measures ANOVA tested group × time differences.
Results
At baseline, OCDUS scores did not differ between groups (Active: 32.00 ± 2.47 vs. Sham: 31.60 ± 2.85; F (1,38) = 0.582, p = 0.582, η2p = 0.015). Following treatment, the Active group showed markedly greater reductions in craving than Sham at Day 5 (10.35 ± 2.21 vs. 24.25 ± 5.29; F(1,38) = 956.5, p < 0.001, η2ₚ = 0.672) and Day 14 (6.30 ± 1.98 vs. 20.75 ± 5.22; F(1,38) = 99.56, p < 0.001, η2ₚ = 0.503), with effects maintained at Day 28 (5.75 ± 1.65 vs. 23.35 ± 6.07).
Conclusion
Five sessions of right-DLPFC tDCS produced rapid, significant, and sustained reductions in opioid craving compared with sham, supporting its promise as an adjunctive treatment in opioid use disorder.
期刊介绍:
General Hospital Psychiatry explores the many linkages among psychiatry, medicine, and primary care. In emphasizing a biopsychosocial approach to illness and health, the journal provides a forum for professionals with clinical, academic, and research interests in psychiatry''s role in the mainstream of medicine.